electroCore (ECOR) Set to Announce Quarterly Earnings on Wednesday

electroCore (NASDAQ:ECOR) will be issuing its quarterly earnings data after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of ($0.39) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

electroCore (NASDAQ:ECOR) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.03). The company had revenue of $5.44 million during the quarter, compared to analyst estimates of $5.18 million. electroCore had a negative net margin of 88.12% and a negative return on equity of 219.33%. On average, analysts expect electroCore to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

electroCore Stock Performance

ECOR traded up $0.05 during trading on Tuesday, reaching $5.80. 8,918 shares of the stock were exchanged, compared to its average volume of 11,278. The stock has a market cap of $37.41 million, a P/E ratio of -2.02 and a beta of 0.55. The stock’s 50 day moving average price is $6.27 and its two-hundred day moving average price is $6.51. electroCore has a twelve month low of $4.50 and a twelve month high of $8.08.

Insider Activity at electroCore

In other electroCore news, CEO Daniel S. Goldberger purchased 38,505 shares of the stock in a transaction on Wednesday, June 5th. The shares were purchased at an average price of $6.43 per share, with a total value of $247,587.15. Following the completion of the transaction, the chief executive officer now directly owns 249,565 shares in the company, valued at $1,604,702.95. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 13.14% of the stock is currently owned by company insiders.

electroCore Company Profile

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.